Invesco Dynamic Pharmaceuticals ETF (PJP)

NYSEARCA: PJP · IEX Real-Time Price · USD
70.17
0.00 (0.00%)
Sep 26, 2022 12:00 AM EDT - Market open
0.00%
Assets $315.12M
NAV $70.81
Expense Ratio 0.58%
PE Ratio 15.45
Shares Out 4.45M
Dividend (ttm) $0.76
Dividend Yield 1.09%
Ex-Dividend Date Sep 19, 2022
1-Year Return -10.68%
Volume 50
Open 70.45
Previous Close 70.17
Day's Range 70.06 - 70.91
52-Week Low 68.59
52-Week High 84.11
Beta 0.75
Holdings 26
Inception Date Jun 23, 2005

About PJP

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.

Asset Class Equity
Sector Biotech
Region North America
Issuer Invesco
Stock Exchange NYSEARCA
Ticker Symbol PJP
Index Tracked Dynamic Pharmaceutical Intellidex Index

Top 10 Holdings

55.23% of assets
Name Symbol Weight
AbbVie ABBV 6.14%
Johnson & Johnson JNJ 5.98%
Eli Lilly and Company LLY 5.89%
Gilead Sciences GILD 5.89%
Merck & Co. MRK 5.74%
Abbott Laboratories ABT 5.66%
Amgen AMGN 5.53%
Pfizer PFE 5.47%
Bausch Health Companies Inc BHC.TO 4.79%
Regeneron Pharmaceuticals REGN 4.14%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Sep 19, 2022 $0.169 Sep 23, 2022
Jun 21, 2022 $0.20676 Jun 30, 2022
Mar 21, 2022 $0.20153 Mar 31, 2022
Dec 20, 2021 $0.1845 Dec 31, 2021
Sep 20, 2021 $0.175 Sep 30, 2021
Jun 21, 2021 $0.14784 Jun 30, 2021
Full Dividend History

News

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

Sector ETF report for PJP

2 weeks ago - Zacks Investment Research

Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

1 month ago - Zacks Investment Research

Pharma & Biotech ETFs at One-Month High: Here's Why

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.

2 months ago - Zacks Investment Research

Pharma ETFs in Focus Post Q1 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols: FTXHIHEPPHXPH
4 months ago - Zacks Investment Research

Solid Q4 Earnings Fail to Impress Pharma ETFs

Solid earnings failed to impress pharma ETFs over the past month due to a broad sell-off in the market.

Other symbols: FTXHIHEPPHXPH
7 months ago - Zacks Investment Research

Big Pharma Innovation Outlook Looks Healthy

Pharmaceuticals companies, even the old, large-cap variety, are innovators in their own right. They have to be.

9 months ago - ETF Trends

Economics, Patents Critical for Pharmaceuticals Innovation, Equity Prices

The S&P 500 Health Care Index is up 18% year-to-date, an admiral though not spectacular performance. While coronavirus vaccines remain a point of much discussion, pharmaceuticals stocks also fit the bil...

10 months ago - ETF Trends

Wave of Solid Q3 Earnings Push Pharma ETFs Higher

The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.

Other symbols: FTXHIHEPPHXPH
10 months ago - Zacks Investment Research

Blue-Chip Pharmaceuticals Stocks Contend With Political Headwinds

The Invesco Dynamic Pharmaceuticals ETF (NYSEArca: PJP) is off 3.66% month-to-date, and the source of that lethargy is easy to spot: The drug price reform debate is once again gaining momentum, promptin...

1 year ago - ETF Trends

Looking for Healthier Healthcare Stocks?

The healthcare sector is getting its groove back, as a variety of exchange traded funds dedicated to the group are printing or residing near new highs. The Invesco Dynamic Pharmaceuticals ETF (NYSEArca:...

1 year ago - ETF Trends

Pharma ETFs Gain on Q2 Earnings

Many industry bigwigs reported solid results with some beating on earnings or revenues or both.

Other symbols: FTXHIHEPPHXPH
1 year ago - Zacks Investment Research

Pharma & Healthcare ETFs at a One-Year High: Here's Why

Upbeat earnings, COVID-19-related sales, compelling valuation and lucrative dividend prospects are boosting pharma and healthcare ETFs.

Other symbols: FXHIEIHIHEPPH
1 year ago - Zacks Investment Research

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Other symbols: FTXHIHEPPHXPH
1 year ago - Zacks Investment Research

ETFs to Watch Ahead of Georgia Senate Runoff

Stocks came crashing on the first day of the New Year in apprehension of the outcome of the Georgia run-off elections.

1 year ago - Zacks Investment Research

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other symbols: BBHFBTPBEPPH
1 year ago - Zacks Investment Research

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Other symbols: FTXHPPHPSCHXHSXPH
1 year ago - Zacks Investment Research

Vaccine Hopes & Divided Government: Sector ETFs to Win

News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.

Other symbols: IHFJETSKREROOFRYE
1 year ago - Zacks Investment Research

ETF Areas to Win/Lose With Biden on the Verge of Victory

Though the counting process for the U.S. election outcome is still on, the prospect of a Joe Biden presidency marked by a divided Congress is rife.

1 year ago - Zacks Investment Research

Here's Why Healthcare ETFs Are Rallying Post Elections

Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.

Other symbols: IBBPPHVHTXBIXLV
1 year ago - Zacks Investment Research

Wining & Losing Sector ETFs Post Election Day

Chances of a dividend congress caused a superb rally in Wall Street the day after election.

Other symbols: CLOUFDNHCAIHFKBEQQQXLK
1 year ago - Zacks Investment Research

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Other symbols: FTXHIHEPPHXPH
1 year ago - Zacks Investment Research

Healthcare ETFs: Winners & Losers in the Light of U.S. Election

The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.

Other symbols: CNBSGNOMIHEIHFIHIXHE
1 year ago - Zacks Investment Research

Best Pharmaceutical ETFs for Q4 2020

The best pharmaceutical ETFs for Q4 2020 are KURE, XPH, and PJP.

Other symbols: KUREXPH
2 years ago - Investopedia

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Other symbols: FTXHIHEPPHXPH
2 years ago - Zacks Investment Research

5 Sector ETFs Just Got Upgraded to Buy

Zacks recently issued quarterly rank updates for ETFs and these sector ETFs have been upgraded to Buy.

Other symbols: IYJIYZKBERTHVFHVOXXPH
2 years ago - Zacks Investment Research